GLOW (GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

One subcutaneous injection once daily, at a consistent time of day, for all 28 days of the course. The dose is flat across the whole 4 week block, so every injection is the same 10 units (0.10 mL), delivering approximately 1.7 mg GHK-Cu, 0.33 mg TB-500, and 0.33 mg BPC-157. At a draw this small, a 0.3 mL 30 unit or a 0.5 mL 50 unit U-100 insulin syringe reads far more cleanly than a 100 unit barrel. Sites are rotated systematically across abdomen, thighs, and upper arms, keeping successive injections at least 1 to 2 inches apart.

Results Timeline

Sequence described in the research record. Individual response varies.

• Day 1: reconstitute the 70 mg vial with 3.0 mL bacteriostatic water and label it with the date; the vial now holds 30 daily doses at 10 units each.
• Weeks 1 to 4: one 10 unit (0.10 mL) subcutaneous injection per day, unchanged, for 28 consecutive days.
• End of week 4: the 28 day course and the 28 day beyond use date of the reconstituted solution run out together, so any remaining solution is discarded rather than carried forward.
• Weeks 5 to 8: a 2 to 4 week rest period with no injections before any further cycle is considered.

Reconstitution Steps

1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl or roll until dissolved (do not shake).
4. Label with date and concentration; refrigerate at 2 to 8 °C, protected from light. At 23.33 mg/mL, 1 unit = 0.01 mL » 233.33 mcg of total blend on a U-100 insulin syringe, which is 166.67 mcg GHK-Cu, 33.33 mcg TB-500, and 33.33 mcg BPC-157.
5. Use within 4 weeks (28 days) for potency and safety.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at minus 20 °C or below for long term stability, months to over a year. Where no freezer is available, 2 to 8 °C is acceptable for shorter durations.
• Reconstituted: refrigerate at 2 to 8 °C whenever not in use, never freeze the reconstituted solution, and discard after 4 weeks (28 days).

• Allow frozen vials to reach room temperature before opening, which prevents condensation inside the vial.
• Protect the reconstituted solution from light and inspect it before each use; discard if discolored, cloudy, or carrying any precipitate.

Supplies Needed

Planning figures assume the full 4 week daily course at 2,330 mcg of total blend per injection, which is 16.31 mg of blend per week.

Peptide Vials (GLOW, per vial):

• The 28 day course consumes about 65.2 mg of blend, so one 70 mg GLOW vial covers the entire cycle.

Insulin Syringes (U-100):

• 7 U-100 insulin syringes per week, one per daily injection.
• 28 syringes across the full 4 week cycle; 0.3 mL 30 unit barrels give the clearest read at a 10 unit draw.

Bacteriostatic Water (10 mL bottles):

• 3.0 mL of bacteriostatic water reconstitutes one 70 mg vial, so a single 10 mL bottle covers three vials with volume left over.

Alcohol Swabs:

• 2 alcohol swabs per injection, one for the vial stopper and one for the skin.
• 56 swabs across the full 4 week cycle, well inside a single 100 count box.

Important Notes

Practical considerations for consistency and safety.

• Use a new sterile insulin syringe for every injection and place it in a sharps container immediately afterward.
• Rotate injection sites systematically across abdomen, thighs, and upper arms, keeping each injection at least 1 to 2 inches from the last.
• Inject slowly over 2 to 3 seconds and wait a few seconds before withdrawing the needle.
• Log the daily dose, the injection site, and any observations; a written record is what keeps a 28 day course consistent.
• Practice aseptic technique every time: clean the vial stopper and the skin with separate alcohol swabs and let both air dry completely.
• Regulatory Note: GLOW is a research blend, not an approved medicine. Its three components carry no drug approval for these uses, and large scale human clinical trials are still needed to confirm efficacy and safety for specific indications. The material is supplied for research use only and not for human consumption.

How This Works

The three peptides in GLOW operate through distinct but complementary pathways. GHK-Cu acts as a genomic modulator, upregulating genes tied to tissue growth while downregulating those linked to inflammation and tissue breakdown; it stimulates collagen and glycosaminoglycan synthesis in fibroblasts, promotes angiogenesis, and carries antioxidant and anti-inflammatory activity. TB-500, a fragment of Thymosin beta 4, mainly drives cell migration and cytoskeletal remodeling by binding actin, mobilizing cells toward injury sites, accelerating angiogenesis, and recruiting stem and progenitor cells. BPC-157 triggers a multi-factorial healing response: it enhances growth factor signaling through VEGF and PDGF, upregulates nitric oxide pathways for improved microcirculation, counteracts inflammatory mediators, and promotes the migration and survival of repair cells. Combining the three puts collagen synthesis, cell migration, angiogenesis, and inflammation control into a single protocol.

Benefits & Side Effects

Observations from the published record.

• Accelerated wound healing: Thymosin beta 4 improved the closure rate of chronic skin wounds in clinical trials and animal models, BPC-157 has shown enhanced healing in tendon, muscle, bone, and gut injuries, and GHK-Cu aids wound contraction and epithelialization.
• Anti-inflammatory and pain reduction: all three components mitigate inflammation at injury sites through complementary pathways.
• Improved tissue quality and reduced fibrosis: TB-500 minimizes fibrous scar tissue, BPC-157 supports organized collagen deposition, and GHK-Cu boosts proper collagen and extracellular matrix production.
• Multi-tissue regeneration: the literature spans orthopedic injuries, dermatologic uses, and potentially gastrointestinal repair.
• Tolerability: generally well tolerated, with occasional mild injection site reactions such as redness or itching.
• Evidence limit: large scale human clinical trials are still needed to confirm efficacy and safety for specific indications.

Lifestyle Factors

Complementary strategies for best outcomes.

• Adequate protein intake, 1.6 to 2.2 g/kg of body weight daily, supplies the substrate for collagen synthesis and tissue repair.
• Progressive resistance training with activity modification matched to the healing goal.
• Sleep quality of 7 to 9 hours nightly, the primary recovery window for tissue regeneration.
• Hydration plus adequate micronutrients, particularly vitamin C, zinc, and copper, alongside stress management to support a favorable healing hormonal environment.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Pickart L. Regenerative and Protective Actions of the GHK-Cu Peptide in Light of New Gene Data (Int J Mol Sci, 2018).
2. Thymosin beta 4 Promotes Dermal Healing (Vitamins & Hormones, 2016).
3. Thymosin beta 4: A Multi-Functional Regenerative Peptide (Expert Opinion on Biological Therapy, 2012).
4. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (HSS Journal, 2025).